Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$87.59 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.11M
Market Cap
$5.78B
Enterprise Value$7.06B
Total Cash (Recent Filing)$29.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Apr 30, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding56,567,387
10 Day Avg. Volume1,122,966
30 Day Avg. Volume1,114,933
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.08
Price to Cash Flow (P/CF)2754.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.54
Enterprise Value/Ebitda-77.43
Forecast
1Y Price Target
$164.50Price Target Upside60.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Glaukos News
PremiumCompany Announcements
Glaukos Highlights Strategic Focus in 2024 Presentation
PremiumCompany Announcements
Glaukos Corp. Reports Record Sales in Earnings Call
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIDose sales nearly doubled in 4Q to ~$15.5M and are expected to reach $100M+ in FY25, indicating strong growth potential for this product.
International MarketsOUS Glaucoma is experiencing growth greater than 20%, showing a strong international market presence despite challenges.
Product DevelopmentGlaukos Corp is more optimistic about the iDose opportunity due to positive clinical outcomes, improved surgeon training, and reimbursement progress.
Bears Say
Market ConcernsShares of Glaukos Corp. experienced a decline due to concerns about the 2025 US iDose outlook, particularly related to local coverage determinations affecting the core US MIGS franchise.
Regulatory ChallengesChallenges with Novitas have led to some iDose procedure halts due to delays in facility fee payments, although this has been resolved for some but remains an issue for others.
Sales PerformanceUS MIGS sales were negatively impacted by local coverage determinations, leading to a slower growth rate.
---
Ownership Overview
5.91% Insiders
41.96% Mutual Funds
0.19% Other Institutional Investors
26.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $87.59 and its highest was $163.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $5.78B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Apr 30, 2025 which is in 37 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Feb 20, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.383 by -$0.017.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.35.
How many shares outstanding does Glaukos have?
Glaukos has 56,567,387 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.383. Following the earnings report the stock price went down -20.005%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
---
Glaukos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$164.50 (60.86% Upside)
$164.50 (60.86% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 22.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.84%
12-Months-Change
Fundamentals
Return on Equity
-23.83%
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record sales growth, driven by the U.S. and international glaucoma franchises, and positive clinical developments. However, challenges such as LCD impacts, foreign exchange headwinds, and Medicaid rebate effects on corneal health were noted. The company remains optimistic about its strategic plans and financial position.Read More>---
GKOS Stock 12 Month Forecast
Average Price Target
$164.50
▲(60.86% Upside)
Technical Analysis
Align Tech
―
ICU Medical
―
Johnson & Johnson
―
Staar Surgical
―
Zimmer Biomet Holdings
―
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+17.22%
upgraded a buy rating 3 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +17.22% per trade.
---